CN108578443A - The preparation method of armillaria mellea and its application in terms of anti-trioxypurine - Google Patents
The preparation method of armillaria mellea and its application in terms of anti-trioxypurine Download PDFInfo
- Publication number
- CN108578443A CN108578443A CN201810179049.6A CN201810179049A CN108578443A CN 108578443 A CN108578443 A CN 108578443A CN 201810179049 A CN201810179049 A CN 201810179049A CN 108578443 A CN108578443 A CN 108578443A
- Authority
- CN
- China
- Prior art keywords
- preparation
- halimasch
- filtrate
- armillaria mellea
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000221226 Armillaria mellea Species 0.000 title claims abstract description 35
- 235000011569 Armillaria mellea Nutrition 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000000284 extract Substances 0.000 claims abstract description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000000706 filtrate Substances 0.000 claims abstract description 34
- 238000000605 extraction Methods 0.000 claims abstract description 24
- 238000000926 separation method Methods 0.000 claims abstract description 15
- 230000003292 diminished effect Effects 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 14
- 201000005569 Gout Diseases 0.000 claims abstract description 11
- 239000012141 concentrate Substances 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 9
- 150000001298 alcohols Chemical class 0.000 claims abstract description 6
- 238000000638 solvent extraction Methods 0.000 claims abstract description 4
- 235000019441 ethanol Nutrition 0.000 claims description 37
- 201000001431 Hyperuricemia Diseases 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000005292 vacuum distillation Methods 0.000 claims description 8
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 7
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 7
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 7
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 7
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000002137 ultrasound extraction Methods 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000002893 slag Substances 0.000 claims description 3
- 239000012752 auxiliary agent Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 241000283707 Capra Species 0.000 abstract description 4
- 206010061623 Adverse drug reaction Diseases 0.000 abstract description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract description 2
- 230000007613 environmental effect Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical group OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 19
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 18
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 16
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 15
- 229960003459 allopurinol Drugs 0.000 description 15
- 229940116269 uric acid Drugs 0.000 description 15
- 210000002700 urine Anatomy 0.000 description 14
- 108010093894 Xanthine oxidase Proteins 0.000 description 10
- 102100033220 Xanthine oxidase Human genes 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 229940109239 creatinine Drugs 0.000 description 9
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 8
- 229960002529 benzbromarone Drugs 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 230000003907 kidney function Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 108091006303 SLC2A9 Proteins 0.000 description 4
- 102100030935 Solute carrier family 2, facilitated glucose transporter member 9 Human genes 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 108091006739 SLC22A6 Proteins 0.000 description 3
- 102100036930 Solute carrier family 22 member 6 Human genes 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- -1 sesquiterpene aryl ester Chemical class 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101000821827 Homo sapiens Sodium/nucleoside cotransporter 2 Proteins 0.000 description 2
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100021541 Sodium/nucleoside cotransporter 2 Human genes 0.000 description 2
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- CPWPJLJWUXOOAB-UHFFFAOYSA-N benzene;bromine Chemical compound [Br].C1=CC=CC=C1 CPWPJLJWUXOOAB-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010010 raising Methods 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 102000014778 Concentrative nucleoside transporters Human genes 0.000 description 1
- 108050005111 Concentrative nucleoside transporters Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical compound CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Effect the present invention relates to a kind of preparation method of armillaria mellea and its in terms of anti-trioxypurine, including：(1) it crushes；(2) it is extracted with 5 25 times of alcohols solvents at 40 75 DEG C, is filtered under diminished pressure separation filter residue and filtrate, repeat extraction three times；(3) it is evaporated under reduced pressure and concentrates after merging the filtrate obtained by step (2), alcohol extract is obtained after dry；(4) it uses water to be filtered under diminished pressure separation filter residue and filtrate as the halimasch residue 0.5 3 hours of solvent extraction step (2) at 40 100 DEG C, repeats extraction three times；(5) it is evaporated under reduced pressure and concentrates after merging the filtrate obtained by step (4), be dried to obtain water extract.The preparation process of the present invention is simple, at low cost；Safety and environmental protection；Armillaria mellea of the present invention has significant anti-trioxypurine effect, and Small side effects, can be used in preparing the drug for alleviating gout illness, and new direction is provided to improve the big phenomenon of current goat drug side-effect.
Description
Technical field
The present invention relates to a kind of extract and its pharmacological actions, and in particular to a kind of preparation method of armillaria mellea and
Its effect in terms of anti-trioxypurine.
Background technology
Goat seriously perplexs human lives, and the epidemiological study of New Zealand, the U.S. and China shows that gout illness becomes
Must be more and more common, incidence is about 2%, and is constantly increased.Wherein, 65 years old and above crowd's incidence highest, the hair of male
Sick rate is twice also higher than women incidence.
Goat be hyperuricemia development as a result, be due to internal uric acid concentration higher than blood solvability (>360μ
Mol/L), sodium urate crystals are caused to be deposited in soft tissue, joint, these depositing crystallines cause soft tissue, joint and bone tissue anti-
Inflammatory severe pain is recurred, to seriously reduce patients ' life quality.
Halimasch is a kind of very popular traditional edible mushroom, with Chinese Famous gastrodia elata symbiosis.China, South Korea and
Japan, due to its delicious flavour, flavor is dense, therefore becomes dining table delicacies.Other than nutritive value, the Chinese medicine in traditional Chinese medicine
It also be used to treat headache medicine, have a sleepless night, the diseases such as dizzy and hypertension.
In terms of nearest research has been focused on the pharmacology of halimasch.So far, it is had discovered that in halimasch
A large amount of secondary metabolites, including steroids, alkaloid, Diterpenes, triterpenes, pigment, sesquiterpenoids aromatic ester, prophyll alkene
Base horse triterpene derivative ester, sesquiterpene aryl ester, diketopiperazine, polyphenol, ascorbic acid etc..It is interesting that in these compounds
It is most of show different bioactivity, such as anti-inflammatory, antitumor, immunological regulation, radioresistance, antibacterial, anti-aging is anti-oxidant
It is protected with DNA.
However, there is presently no the reports about its inhibiting hyperuricemia and gout etc. in terms of anti-trioxypurine.
Invention content
For the above deficiency, preparation method and its answering in terms of anti-trioxypurine that the present invention provides a kind of armillaria mellea
With, the preparation method using cheap and resourceful, environmental-friendly alcohols such as second alcohol and water, can reduce cost,
Organic solvent pollution is avoided, and the purity of the extract prepared is high, effect in terms of anti-trioxypurine protrudes.
The present invention reaches above-mentioned purpose by following scheme：
In the first aspect of the present invention, a kind of preparation method of armillaria mellea is provided, is included the following steps：
(1) dry halimasch fructification or mycelium or tunning are crushed；
(2) it is extracted with 5-25 times of alcohols solvent at 40-75 DEG C, is filtered under diminished pressure separation filter residue and filtrate, it will be isolated
Filter residue repeats extraction three times with alcohol reagent；
(3) it is evaporated under reduced pressure and concentrates after merging the filtrate obtained by step (2), alcohol extract (GAE) is obtained after dry；
(4) water is used at 40-100 DEG C as halimasch residue 0.5-3 hours of solvent extraction step (2), is filtered under diminished pressure point
Extraction is repeated from filter residue and filtrate, and by filter residue water three times；
(5) it is evaporated under reduced pressure and concentrates after merging the filtrate obtained by step (4), be dried to obtain water extract (GAW).
Preferably, the alcohols solvent of above-mentioned steps (2) includes but not limited to ethyl alcohol, methanol and its mixed solvent with water.
Preferably, above-mentioned steps (2) are：It is extracted 0.5-5 hours with 5-20 times of ethyl alcohol at 40-65 DEG C, is filtered under diminished pressure separation
Filter residue and filtrate.
It is further preferred that the Extracting temperature in the step (2) is 60 DEG C.
Preferably, vacuum distillation is concentrated into 25-250mL after the filtrate of the step (2) merges, and alcohol extracting is obtained after dry
Object.
Preferably, the Extracting temperature of the step (4) is 85 DEG C.
Preferably, the extraction time of the step (4) is 3 hours.
Preferably, vacuum distillation is concentrated into 25-250mL after the filtrate of the step (5) merges, and obtaining water after dry carries
Object.
Preferably, the extract process of the step (2) is ultrasonic extraction.
Preferably, the extraction process of the step (4) is ultrasonic extraction.
In a preferred embodiment, a kind of preparation method of armillaria mellea, includes the following steps：
(1) dry halimasch fructification or mycelium or tunning are crushed；
(2) it is extracted 0.5-5 hours with 5-20 times of EtOH Sonicate at 40-65 DEG C, is filtered under diminished pressure separation filter residue and filtrate, will divided
Extraction is repeated from obtained filter residue ethyl alcohol three times；
(3) it is evaporated under reduced pressure and concentrates after merging the filtrate obtained by step (2), alcohol extract (GAE) is obtained after dry；
(4) water is used to depressurize as halimasch residue 0.5-3 hours of solvent supersonic extraction step (2) at 40-100 DEG C
Filter separation filter residue and filtrate, and filter residue water is repeated into extraction three times；
(5) it is evaporated under reduced pressure and concentrates after merging the filtrate obtained by step (4), be dried to obtain water extract (GAW).
In another preferred embodiment, a kind of preparation method of armillaria mellea, includes the following steps：
(1) dry halimasch fructification or mycelium or tunning are crushed；
(2) it is extracted 0.5-5 hours with 5-20 times of EtOH Sonicate at 60 DEG C, is filtered under diminished pressure separation filter residue and filtrate, will detach
Obtained filter residue repeats extraction three times with ethyl alcohol；
(3) vacuum distillation is concentrated into 25-250mL after merging the filtrate obtained by step (2), and alcohol extract is obtained after dry
(GAE)；
(4) water is used at 85 DEG C as the halimasch residue 3 hours of solvent supersonic extraction step (2), is filtered under diminished pressure separation filter
Slag and filtrate, and filter residue water is repeated into extraction three times；
(5) vacuum distillation is concentrated into 25-250mL after merging the filtrate obtained by step (4), is dried to obtain water extract
(GAW)。
In another preferred embodiment, a kind of preparation method of armillaria mellea, includes the following steps：
(1) dry halimasch fructification or mycelium or tunning are crushed；
(2) it is extracted 0.5-5 hours with 5-20 times of EtOH Sonicate at 40-65 DEG C, is filtered under diminished pressure separation filter residue and filtrate, will divided
Extraction is repeated from obtained filter residue ethyl alcohol three times；
(3) it is evaporated under reduced pressure and concentrates after merging the filtrate obtained by step (2), alcohol extract (GAE) is obtained after dry；
(4) water is used to depressurize as halimasch residue 0.5-3 hours of solvent supersonic extraction step (2) at 40-100 DEG C
Filter separation filter residue and filtrate, and filter residue water is repeated into extraction three times；
(5) it is evaporated under reduced pressure and concentrates after merging the filtrate obtained by step (4), be dried to obtain water extract (GAW).
In the second aspect of the present invention, a kind of armillaria mellea that above-mentioned preparation method is prepared, including honey are provided
Ring mykol extract, halimasch water extract, the halimasch alcohol extract includes ethanol extract.
In above-mentioned armillaria mellea, ergosterol total content is 1-10000 μ g/g.
In above-mentioned halimasch alcohol extract, ergosterol total content is about 30 μ g/g.
In above-mentioned halimasch water extract, ergosterol total content is about 3 μ g/g.
Include that alcohol extract and water extract carry out dropping urine in Mice Body using armillaria mellea made from above-mentioned preparation method
Acid experiment, the results showed that, using halimasch extract continuous gavage 7 days, alcohol extract can be by the blood uric acid concentration of high lithemia mouse
It is reduced to slightly less than normal mouse uric acid level, effect is better than positive drug Benzbromarone；Water extract can be by the blood of high lithemia mouse
Liquid uric acid concentration is reduced to a little higher than normal mouse uric acid level, and effect is suitable with Benzbromarone.
Based on this kind of above-mentioned halimasch extract, including halimasch alcohol extract, honey are provided in the third aspect of the present invention
Application of the ring bacterium water extract in terms of anti-trioxypurine.
Preferably, a kind of above-mentioned halimasch extract, including halimasch alcohol extract, halimasch water extract, in anti-antihyperuricemic
The application of disease and gout etc..
Preferably, a kind of above-mentioned halimasch extract, including halimasch alcohol extract, halimasch water extract are preparing anti-high urine
Application in the drug of the diseases such as acidaemia and gout.
In the fourth aspect of the present invention, a kind of preparation for treating gout, hyperuricemia is provided, the preparation includes above-mentioned
Armillaria mellea, including halimasch alcohol extract and/or halimasch water extract.
Preferably, the preparation includes drug, health products, auxiliary agent or food.
In the fifth aspect of the present invention, a kind of drug for treating gout, hyperuricemia is provided, the drug includes above-mentioned
Armillaria mellea and pharmaceutically acceptable carrier, the armillaria mellea include halimasch alcohol extract and/or halimasch
Water extract.
The beneficial effects of the present invention are：
1, the preparation process of armillaria mellea of the present invention is simple, at low cost；
2, the present invention includes ethyl alcohol, water as solvent extraction halimasch using alcohol reagent, and there is no organic solvent pollutions
Or the problem of residual, safety and environmental protection；
3, the purity of the armillaria mellea of preparation method of the present invention is high, and pharmacological action protrudes；
3, armillaria mellea of the present invention has significant anti-trioxypurine effect, and Small side effects, can be used in preparing and alleviate
The drug of gout illness provides new direction to improve the big phenomenon of current goat drug side-effect.
Description of the drawings
Fig. 1 is each group mice serum uric acid level in test example 1.
Fig. 2 is each group mouse urine uric acid level in test example 1.
Fig. 3 is each group mice serum urea nitrogen levels in test example 1.
Fig. 4 is each group mouse urine urea nitrogen levels in test example 1.
Fig. 5 is each group mice serum creatinine level in test example 1.
Fig. 6 is each group mouse urine creatinine level in test example 1.
Specific implementation mode
Below in conjunction with specific embodiment, invention is further explained.
Embodiment 1：
The preparation of halimasch ethanol extract：
(1) the halimasch fructification by 100g dryings crushes；
(2) it is extracted 3 hours with 2L EtOH Sonicates at 60 DEG C, separation filter residue and filtrate is filtered under diminished pressure, by isolated filter
Slag repeats extraction three times with ethyl alcohol；
(3) vacuum distillation is concentrated into 25-250mL after merging the filtrate obtained by step (2), and ethyl alcohol extraction is obtained after dry
Object (GAE).
The yield 5.88g for the halimasch ethanol extract being prepared, yield 5.88%.
Embodiment 2：
The preparation of halimasch water extract：
By halimasch residue isolated in embodiment 1, use water as the honey of solvent supersonic extraction step (2) at 85 DEG C
Ring bacterium residue 3 hours is filtered under diminished pressure separation filter residue and filtrate, and filter residue water is repeated extraction three times；The filtrate of gained merges
Vacuum distillation is concentrated into 25-250mL afterwards, is dried to obtain water extract (GAW).
The yield 8.89g for the halimasch water extract being prepared, yield 8.89%.
Ergosterol measures in 3 armillaria mellea of embodiment
The halimasch ethanol extract of embodiment 1 is measured using HPLC methods and the halimasch water extract of embodiment 2 carries out
Quantitative Determination of Ergosterol, conditional are C18 columns, methanol elution, flow velocity 1mL/min, Detection wavelength 283nm, column temperature 25
DEG C, it is 35 μ g/g to measure in above-mentioned halimasch ethanol extract Quantitative Determination of Ergosterol, ergot steroid in above-mentioned halimasch water extract
Alcohol content is 2.5 μ g/g.
1 armillaria mellea anti-trioxypurine of test example is tested
(1) granted zoopery (authentication code：GT-IACUC20170623-1；GuangZhou, China), in Guangdong Province microorganism
Research institute carries out.From Guangdong Medical Lab Animal Center (Guangzhou), male mouse of kunming (SPF, 20 ± 2 grams) is brought.Suitable
After answering environment 1 week, mouse height urine is established by giving PO (Oteracil Potassium, 100mg/kg) and HX (hypoxanthine, 500mg/kg)
Acidaemia animal model.
Animal is assigned randomly to several groups (n=10), including normal group, hyperuricemia group, allopurinol group and benzene bromine
The grand control group of horse and low dosage (30mg/kg), middle dosage (60mg/kg) and high dose (120mg/kg) are respectively provided with AME
With the medicine group of AMW.Allopurinol and Benzbromarone are recombinated in water to prepare the solution of 0.5 and 0.78mg/mL. 30mg/
The concentration of the AME and AMW of kg, 60mg/kg, 120mg/kg dosage are respectively 3mg/mL, 6mg/mL and 12mg/mL.Allopurinol
Administration Allopurinol (5mg/kg) and Benzbromarone (7.8mg/kg) are compareed with Benzbromarone.For AME and AMW groups, mouse difference
With 30mg/kg, 60mg/kg, 120mg/kg and 30mg/kg, AME and AMW is administered in 60mg/kg, 120mg/kg.Other groups are given
The physiological saline (0.9%) of respective volume.Therapy lasted 1 week, is repeated once daily.Continuous 7 days, and it is right at the 1st, 3,5,7 day
Mouse is weighed record.
For (2) the 7th days gastric infusions after 1 hour, execution takes blood and urine to be centrifuged under 3500r/min speed using centrifuge
The isolated serum of blood sample obtained by 10min is stored in -20 DEG C.Win mice organs official, including liver, spleen, kidney.
It is used in combination normal saline solution to wash.Then it is blotted, is weighed with plain filter.
(3) gained serum and urine in (2) is taken to measure serum uric acid level, urine uric acid level, serum urea nitrogen respectively
With creatinine level and urine urea nitrogen and creatinine level.
(4) statistical analysis is carried out using expert data processing routine SPSS (Release 11.5, SPSS Inc., 2001).
All data are expressed as mean+/-standard error (S.D.), and are analyzed by one-way analysis of variance (ANOVA), and lead to
It crosses double tail Student's t inspections and compares cell mean.Statistically significant (the P of difference<0.05 or P<0.01) the following symbol of use
Number indicate：It is compareed with normal group variant：*P<0.05, * * P<0.01；It is compareed with the PO and HX hyperuricemia model groups induced
It is variant,#P<0.05,##P<0.01；Compareed with allopurinol group it is variant,△P<0.05,△△P<0.01。
As a result as shown in Figures 1 to 6.
In Fig. 1, oxygen piperazine potassium and hypoxanthic administration make normal mouse blood uric acid (SUA, 145 μm of ol/L) significantly rise
Up to hyperuricemia control group (351 μm of ol/L, P<0.01), it was demonstrated that the success of model.In hyperuricemia mouse (351 μ
Mol/L in), allopurinol (5mg/kg) and Benzbromarone (7.8mg/kg) positive controls SUA be down to 98 μm of ol/L and
180μmol/L (P<0.01) its hyperuricemia model modeling success, is further confirmed.AME 30mg/kg, 60mg/kg and
120mg/kg can obviously reduce hyperuricemia mouse SUA to 136 μm of ol/L, 130 μm of ol/L and 115 μm of ol/L (P<0.01).
Hyperuricemia mouse SUA is down to 250 μm of ol/L by the AMW of 30mg/kg, 60mg/kg and 120mg/kg, 188 μm of ol/L and
152μmol/L(P<0.01)。
Since UUA (urine uric acid) is closely related in terms of maintaining uric acid stable state with SUA (blood uric acid), we have studied AME
Effect with AMW to UUA, as shown in Fig. 2, with Normal group (232 μm of ol/L, P<0.05) it compares, PO and HX can cause height
Uricacidemia control group UUA (241 μm of ol/L) is increased.Allopurinol can reduce hyperuricemia animal UUA (78 μm of ol/L, P<
0.01), this may be since the inhibiting effect of XOD (xanthine oxidase) causes SUA to generate decline.AME 30mg/kg,
60mg/kg and 120mg/kg can be effectively increased UUA to 397 μm of ol/L, 326 μm of ol/L and 272 μm of ol/L (P<0.01), 30mg/
The AMW of kg, 60mg/kg and 120mg/kg are further increased to 575 μm of ol/L, 469 μm of ol/L and 549 μm of ol/L (P<0.01).
It is worth noting that, A.mellea (halimasch) promotes UUA excretions horizontal, this may be the approach of its inhibiting hyperuricemia.
Plasma wrea is not observed between hyperuricemia control (6.09mmol/L) and normal control (6.38mmol/L)
Nitrogen (BUN) marked difference shows that low dose of PO does not influence renal function, as shown in figure 3, allopurinol makes BUN level liters
Up to 11.32mmol/L (P<0.01), part damage renal function.The BUN of AME groups is respectively 8.71mmol/L, 6.97mmol/L
And 9.35mmol/L, AMW group BUN are respectively 9.03mmol/L, 8.40mmol/L and 9.04mmol/L, are below allopurinol pair
According to group (P<0.01).
In addition, giving BUN levels during PO and HX makes normal mouse urinate reduces (7.5mmol/L, P<0.01)
(24.86mmol/L), as shown in Figure 4, it is clear that, allopurinol reduces urine BUN levels, this increases consistent with blood BUN levels.
Benzbromarone makes hyperuricemia mouse retention BUN levels be increased to 20.68mmol/L.Compared with hyperuricemia control group,
30mg/kg, 60mg/kg and 120mg/kg, 30mg/kg, 60mg/kg and 120mg/kgAME and AMW can make urine BUN levels aobvious
Write and increase, respectively 12.57mmol/L, 13.07mmol/L and 14.25mmol/L, 14.49mg/kg, 12.79mg/kg and
12.12mg/kg, 60mg/kg and 120mg/kg restore the normal level of kidney organ.In general, compared with allopurinol,
Influence of the halimasch to renal function reduces.
Creatinine is considered as another important indicator of renal function.Hyperuricemia group serum creatinine (52.7 μm of ol/L) is bright
It is aobvious to be higher than Normal group (48.5 μm of ol/L, P<0.05), as shown in figure 5, allopurinol group is further increased to 55.8 μm of ol/
L (P<0.05), show that kidney has certain damage and renal function.But the creatinine level of AME and AMW is respectively 51.8 μm of ol/
L, 48.2 μm of ol/L and 50.7 μm of ol/L, 53.0 μm of ol/L, 50.5 μm of ol/L and 50.0 μm of ol/L, hence it is evident that be less than allopurinol pair
According to group (P<0.01).
In addition, PO (24.03 μm of ol/L, P<0.05) and HX (26.40 μm of ol/L) makes the reduction of normal mouse urine creatinine level,
As shown in fig. 6, allopurinol (22.17 μm of ol/L, P<0.05) this effect (Fig. 6) is also showed that.Obvious AME and AMW is in height
Creatinine level is increased significantly to 25.85 μm of ol/L, 24.75 μm of ol/L, 24.67 μm of ol/ under the corresponding dosage of uricacidemia mouse
L, 24.96 μm of ol/L, 25.53 μm of ol/L, 27.23 μm of ol/L (P<0.05), showing has renal function certain protective effect.
Compared with normally group mouse, the AME and AMW of all dosage used in this research do not influence weight.And
In allopurinol group, allopurinol significantly inhibits body weight increase.Every other group also has similar coefficient, shows AME and AMW
Influence to liver is little.Compared with Normal group (1.35%), hyperuricemia (1.53%, P<And allopurinol 0.05)
Group (1.58%, P<0.01) Kidney coefficients higher shows that PO and allopurinol have certain negative effect.But AME and AMW
Kidney coefficients be respectively 1.35%, 1.35%, 1.31% and 1.39%, 1.31% and 1.33%, connect very much with normal control
Closely.There is no significant difference between spleen coefficient.
The height of uric acid level in XOD (Xanthine oxidase, xanthine oxidase) direct regulation and control human body.Non- purine
Class precursor substance is converted into purines nucleotide by array of biochemical in vivo, continues to decompose generation hypoxanthine and Huang is fast
Purine eventually passes through the continuous oxidation of XOD and generates uric acid.AME and AMW has XOD activity certain inhibiting effect.It is specific and
Speech, AME inhibits liver XOD activity 19% in 120mg/kg, and allopurinol (5mg/kg) then inhibits 42%.With high lithemia
Mass formed by blood stasis control compare, 120mg/kg AMW will which inhibits 60%.These results can be shown that the anti-trioxypurine of AME and AMW are made
With may be due to the active inhibiting effect of XOD.
In addition, detecting A.mellea to kidney OAT1, the shadow of GLUT9 and URAT1 protein levels by western blot analysis
It rings.Compared with hyperuricemia compares, the protein expression of OAT1 significantly increases in the mouse of AME and AMW processing.With normal control
It compares, PO and HX make the GLUT9 in hyperuricemia control and UTAT1 raisings (P<0.01) AMW makes GLUT9 be substantially reduced, benzene
Bromine Ma Long makes kidney URAT1 reduce (P<0.01).Compared with Benzbromarone, AME does not show similar effect with AMW.This
Outside, influences of the A.mellea to intestines CNT2 protein levels is had studied.AME and AMW makes in the enteron aisle of hyperuricemia mouse
CNT2 protein expressions are lowered.
The above results illustrate that present invention demonstrates the anti-trioxypurine of the armillaria mellea in body hyperuricemia mouse works
With.By reducing XOD activity, raising the kidney expression of OAT1 and lowering kidney GLUT9 and stomach and intestine CNT2, anti-trioxypurine work has been mediated
With.In addition, armillaria mellea is non-toxic to liver,kidney,spleen, it can be used for preparing anti-trioxypurine, the drug for improving gout, health care
In product or assistant medicament.
The above, only preferable specific embodiment of the invention, but scope of protection of the present invention is not limited thereto,
Any one skilled in the art in the technical scope disclosed by the present invention, according to the technique and scheme of the present invention and its
Design is subject to equivalent substitution or change, should all cover within the scope of the present invention.
Claims (10)
1. a kind of preparation method of armillaria mellea, which is characterized in that include the following steps：
(1) dry halimasch fructification or mycelium or tunning are crushed；
(2) it is extracted with 5-25 times of alcohols solvent at 40-75 DEG C, separation filter residue and filtrate is filtered under diminished pressure, by isolated filter residue
Extraction is repeated with alcohol reagent three times；
(3) it is evaporated under reduced pressure and concentrates after merging the filtrate obtained by step (2), alcohol extract is obtained after dry；
(4) water is used at 40-100 DEG C as halimasch residue 0.5-3 hours of solvent extraction step (2), is filtered under diminished pressure separation filter
Slag and filtrate, and filter residue water is repeated into extraction three times；
(5) it is evaporated under reduced pressure and concentrates after merging the filtrate obtained by step (4), be dried to obtain water extract.
2. a kind of preparation method of armillaria mellea according to claim 1, which is characterized in that alcohols solvent include but
It is not limited to ethyl alcohol, methanol and its mix reagent with water.
3. a kind of preparation method of armillaria mellea according to claim 1, which is characterized in that above-mentioned steps (2) are：
It is extracted 0.5-5 hours with 5-20 times of ethyl alcohol at 40-65 DEG C preferably 60 DEG C, is filtered under diminished pressure separation filter residue and filtrate.
4. a kind of preparation method of armillaria mellea according to claim 1, which is characterized in that the step (2)
Vacuum distillation is concentrated into 25-250mL after filtrate merges, and alcohol extract is obtained after dry；And/or the filtrate of the step (5) merges
Vacuum distillation is concentrated into 25-250mL afterwards, and water extract is obtained after dry.
5. a kind of preparation method of armillaria mellea according to claim 1, which is characterized in that the step (4)
Extracting temperature is 85 DEG C；And/or the extraction time of the step (4) is 3 hours.
6. a kind of preparation method of armillaria mellea according to claim 1, which is characterized in that the step (2)
Extract process is ultrasonic extraction；And/or the extraction process of the step (4) is ultrasonic extraction.
7. the armillaria mellea that any preparation method is prepared in a kind of claim 1 to 6, including halimasch alcohol
Extract, halimasch water extract.
8. armillaria mellea according to claim 7, which is characterized in that ergosterol is total in the armillaria mellea
Content is 1-10000 μ g/g.
9. the halimasch extract described in a kind of claim 7 or 8 is in terms of anti-trioxypurine, the application of inhibiting hyperuricemia, gout.
10. a kind of preparation for treating gout, hyperuricemia, the preparation includes the halimasch extraction described in claim 7 or 8
Object, the preparation include drug, health products, auxiliary agent or food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810179049.6A CN108578443A (en) | 2018-03-05 | 2018-03-05 | The preparation method of armillaria mellea and its application in terms of anti-trioxypurine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810179049.6A CN108578443A (en) | 2018-03-05 | 2018-03-05 | The preparation method of armillaria mellea and its application in terms of anti-trioxypurine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108578443A true CN108578443A (en) | 2018-09-28 |
Family
ID=63625710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810179049.6A Pending CN108578443A (en) | 2018-03-05 | 2018-03-05 | The preparation method of armillaria mellea and its application in terms of anti-trioxypurine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108578443A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009234984A (en) * | 2008-03-27 | 2009-10-15 | Ichimasa Kamaboko Co Ltd | Agent for inhibition of lowering or for ameliorating renal function |
| JP2011116673A (en) * | 2009-12-01 | 2011-06-16 | Mie Univ | Uric acid level reducing agent |
| CN107669711A (en) * | 2017-11-23 | 2018-02-09 | 广东省微生物研究所 | The preparation method and its usage of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract |
-
2018
- 2018-03-05 CN CN201810179049.6A patent/CN108578443A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009234984A (en) * | 2008-03-27 | 2009-10-15 | Ichimasa Kamaboko Co Ltd | Agent for inhibition of lowering or for ameliorating renal function |
| JP2011116673A (en) * | 2009-12-01 | 2011-06-16 | Mie Univ | Uric acid level reducing agent |
| CN107669711A (en) * | 2017-11-23 | 2018-02-09 | 广东省微生物研究所 | The preparation method and its usage of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract |
Non-Patent Citations (5)
| Title |
|---|
| TIANQIAO YONG等: "《Hypouricemic Effects of Armillaria mellea on Hyperuricemic Mice Regulated through OAT1 and CNT2》", 1 January 2018 * |
| 倪宗耀: "食用菌的食疗作用与保健功效 ", 《食药用菌》 * |
| 刘葳等: "黄绿蜜环菌多糖的分离纯化与组成结构分析 ", 《长春理工大学学报(自然科学版)》 * |
| 孔令义: "《中药制剂化学》", 28 April 2007, 中国医药科技出版社 * |
| 郭建生等: "《实用临床中药手册》", 31 August 2016 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101033245B (en) | Preparation method and application of pedunculoside | |
| CN107441078A (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN107362194A (en) | Compound celery seed Huai Goat and its medical usage | |
| JPS62129219A (en) | Nutrient for nerve of cerebrospinal system | |
| CN101991580A (en) | Application of lanostane and poria cocos extracts in diabetes treatment | |
| CN113143997A (en) | Application of mulberry extract in preparation of medicine for reducing animal weight | |
| JP2001508777A (en) | Pine needle extract and its use | |
| KR20170027914A (en) | Composition For Preventing or Treating Gout Containing Extracts or Fermentation Metabolites of Dendropanax morbiferus | |
| CN101143157A (en) | Tyrosol and tyrosol bypass salidroside plant extraction and preparation and use thereof | |
| CN102716135B (en) | Lupenone prevents in preparation or treats the application in the product of diabetes | |
| WO2015190872A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity | |
| CN107669711B (en) | Pharmaceutical application of Ganoderma applanatum extract | |
| CN108578443A (en) | The preparation method of armillaria mellea and its application in terms of anti-trioxypurine | |
| CN109771411A (en) | Dihydroquercetin is used to prepare the purposes in the drug for the treatment of fatty liver | |
| JP2005325096A (en) | Monoamine reintake inhibitor compounded with grifola frondosa | |
| CN105012294B (en) | New application of the ellagic acid compounds in treatment antihyperuricemic disease drug is prepared | |
| JP3861295B2 (en) | Blood flow improver | |
| CN111956751A (en) | Pharmaceutical composition for treating hyperuricemia and preparation method thereof | |
| JPH09241157A (en) | Medicinal composition for protecting liver containing lithospermate b | |
| CN1695604A (en) | Medication for treating nerve regression disease of hyperkinetic syndrome of attention defect and depression | |
| CN105982921A (en) | Composition for treating gout and application thereof | |
| CN108888623A (en) | Application of tyrosine protein kinase JAK2 inhibitor BX795 | |
| TWI725485B (en) | Black soybean fermented extract, its preparation method and its use for lowering blood pressure | |
| CN110859847B (en) | Pharmaceutical composition for treating hyperglycemia and atherosclerosis and application thereof | |
| US20090304822A1 (en) | Extract of Polygonum multiflorum Thunb. ex Murray var. hypoleucum and compositions for improving metabolic syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180928 |
|
| RJ01 | Rejection of invention patent application after publication |